📣ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer esmoopen.com/article/S2059-… 👉It has been issued following the approval of 1L NALIRIFOX regimen. 👉Updated 1L and 2L treatment recommendations. 👉Update management algorithm for mPC.

A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in PDAC | ⁦Cancer Discovery⁩ aacrjournals.org/cancerdiscover…

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations | Revolution Medicines #ESMOGI25 ir.revmed.com/news-releases/…

Final COMPASS trial data advanced #PDAC ➡️268 WGS& 253RNA-seq ➡️basal-like& hi GRIm-S ⬇️OS, both unique TME inc CD8 variation,NB primaries vs mets ➡️LTS :HRD, KRAS WT ➡️KRAS major enriches basal, >type II DM ➡️LAPC≠intact SMAD4 ➡️47% receive 2nd line tx nature.com/articles/s4146…

Comparative genomic landscape of acquired resistance in pancreatic cancer treated with pan-RAS or KRASG12C inhibitors - ⁦Annals of Oncology⁩ annalsofoncology.org/article/S0923-…

ESOPEC trial: Recurrence patterns. 🔗 ascopubs.org/doi/10.1200/JC… 📊 CROSS vs FLOT in resectable esophageal ADC: ✔️ Systemic relapse: 67% vs 46% ✔️ Median TTR: 6.6 vs 10.3 mo ✔️ OS after recurrence worse with CROSS. ➡️ Relapse pattern impacts prognosis and follow-up strategy

Genomic profiling unlocks new treatment opportunities for ampullary carcinoma - ESMO - Eur. Oncology esmoopen.com/article/S2059-…

Opportunities for Causal Machine Learning in Precision Oncology NEJM AI ai.nejm.org/doi/full/10.10…

Yes. Writing is not a second thing that happens after thinking. The act of writing is an act of thinking. Writing *is* thinking. Students, academics, and anyone else who outsources their writing to LLMs will find their screens full of words and their minds emptied of thought.

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population [Jul 20, 2021] Ben Westphalen et al. npj Journals Precision Oncology ow.ly/jDyt50FDVB0 #PrecisionMedicine #RWD #openaccess FoundationCORE® database of >295,000 cancer patients

The use of machine learning models to predict PFS and OS outcomes from waterfall plots in RCTs (MAP-OUTCOMES) in ESMO Open. ML tool using depth of response with non-cytotoxic therapies predicting survival, potentially supporting go-no-go decisions. esmoopen.com/article/S2059-…

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer ⁦AACR⁩ aacrjournals.org/cancerres/arti…

Congratulations to Wantong Yao Haoqiang Ying Scott Kopetz & MD Anderson Cancer Center team! New Cell Reports Medicine publication: Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers cell.com/cell-reports-m…

🟠1L treatments of advanced pancreatic cancer ➡️mFOLFIRINOX or S-IROX vs Gem-nab-paclitaxel GENERATE, JCOG1611 Journal of Clinical Oncology ❌mFOLFIRINOX is not superior to Gem-nabPacli ❌No difference in OS, PFS and ORR 👉ascopubs.org/doi/pdf/10.120… ASCO OncoAlert #cancer #oncology #pancreatic

De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer | Nature Communications nature.com/articles/s4146…

The peer-review crisis: how to fix an overloaded system nature.com/articles/d4158…

Can I confidently say to patients that a 3-year structured exercise program may save their lives? The CHALLENGE trial drugdevletter.com/p/can-i-confid…

🆕🗞️Hot off the press! Nature Medicine #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽 More to come with the randomized study📚✔️! Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations. OncoAlert 🔗nature.com/articles/s4159…

Lo studio di fase 3, multicentrico e italiano PANThEON è aperto all’arruolamento anche in IOV - Istituto Oncologico Veneto codiceviola.org/studio-pantheo…

❗️ CONKO-007 Ph 3 RCT: FOLFOX or Gem -> continued chemo vs CRT (50.4 Gy + Gem); surgery if possible Primary endpoint: R0 18% vs 25% in favor of CRT In patients who underwent surgery: 69.4% CRT compared with 50.0% chemotherapy alone ascopubs.org/doi/full/10.12…